Bone neoplasms, which can be either benign or malignant, are abnormal growths in bone tissue. Osteosarcoma, which is more frequent in teens, and chondrosarcoma, which is more common in individuals over 40, are examples of primary bone tumors that start in bone cells. More often, metastatic tumors develop from malignancies such as breast or prostate cancer. Osteochondroma and enchondroma are examples of benign tumors that frequently develop in youngsters and usually cease to grow as the skeleton matures. Fractures, discomfort, and swelling are some of the symptoms. Imaging (MRI, X-rays) and biopsy are used in the diagnosis process. Depending on the type and stage of the tumor, treatment may involve radiation, chemotherapy, or surgery. Only 1% of all malignancies are primary bone cancers. The bone neoplasm pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the bone neoplasm treatment market include AbbVie, Amgen and Actuate Therapeutics Inc., among others.
Leading drugs currently under the pipeline include navitoclax and XGEVA, among others.
The increasing cases of bone neoplasm and the rising technological advancements are poised to positively influence the bone neoplasm pipeline landscape.
The Bone Neoplasm Pipeline Analysis Report by Expert Market Research gives comprehensive insights into bone neoplasm therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for bone neoplasm. The bone neoplasm report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The bone neoplasm pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with bone neoplasm treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to bone neoplasm.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The pathophysiology of bone neoplasms include genetic abnormalities in bone or cartilage-forming cells cause unchecked cell proliferation. Osteoblasts or mesenchymal stem cells give birth to primary malignant tumors such as osteosarcoma, which are triggered by complicated cytogenetic changes (such as hyperploid genotypes) that cause osteoid formation and invasive development. Cartilage cells are the source of chondrosarcomas; peripheral kinds exhibit aneuploidy, whereas central types are associated with near-diploid genetics. Secondary metastatic bone tumors compromise bone integrity when they spread from other cancers, such as breast or lung cancers. Structural weakness brought on by benign or malignant tumors may result in discomfort, fractures, or compression of the nervous system. DNA mutations allow tumors to survive and invade by interfering with normal cell cycle regulation.
The main treatments for bone neoplasms include radiotherapy, chemotherapy, and surgery. The goal of surgery is to remove the tumor; limb-sparing procedures or, if required, amputation may be used. Chemotherapy, which is frequently used both before and after surgery to shrink tumors and stop recurrence, uses potent medications to kill cancer cells. When surgery is not an option, radiotherapy uses high-energy beams to target cancer cells. A multidisciplinary team of experts frequently coordinates treatment programs that are customized based on the patient's health, tumor kind, location, and stage.
Osteosarcoma is the most prevalent kind of malignant bone tumor. Benign tumors are more common in children and adolescents, whereas primary malignant bone tumors usually affect younger populations, especially in the second and third decades of life. In general, incidence rates differ by age and region, with rural areas reporting greater rates than urban ones.
This section of the report covers the analysis of bone neoplasm drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with a substantial number of bone neoplasm drugs undergoing clinical development.
The drug molecule categories covered under bone neoplasm pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The bone neoplasm report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for bone neoplasm.
The EMR report for the bone neoplasm pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed bone neoplasm therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in bone neoplasm clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for bone neoplasm. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of bone neoplasm drug candidates:
AbbVie created Navitoclax, an experimental oral small-molecule inhibitor that targets the proteins B-cell lymphoma 2 (BCL-2) and B-cell lymphoma-extra large (BCL-XL), which are critical for the survival of cancer cells. Navitoclax induces apoptosis in cancerous cells by blocking these proteins. It is presently being assessed in conjunction with ruxolitinib in Phase 1 clinical trials for the treatment of bone neoplasms. Patients with advanced bone-related cancers may benefit from the treatment, which attempts to reduce bone marrow fibrosis and enhance clinical results.
XGEVA (denosumab), developed by Amgen, is a monoclonal antibody that suppresses RANK Ligand (RANKL), a protein required for osteoclast development and activity. By inhibiting RANKL, XGEVA impairs osteoclast-mediated bone resorption, thereby strengthening bone structure. It is authorized to treat unresectable giant cell tumor of bone (GCTB) and to avoid skeletal-related complications in individuals for whom solid tumors have spread to the bone. Phase 4 clinical trials are currently being conducted to further assess XGEVA's long-term safety and effectiveness in treating bone neoplasms.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Bone Neoplasm Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for bone neoplasm. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into bone neoplasm collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share